Galapagos, Roche Expand Alliance into Fibrosis

Galapagos has achieved a $4.7 million milestone in its strategic alliance with Roche. The alliance was also broadened to include novel target and drug discovery in fibrosis.

In January 2010, Galapagos entered its COPD strategic alliance with Roche, which was expanded from small molecule and antibody approaches to include peptides. This expansion covers fibrosis, which is the formation of scar tissue as a result of injury or long-term inflammation in the lungs or other organs.

“Through the alliance with Roche we have yet again proven our ability in novel target discovery across a wide range of disease areas working with human primary cells,” said Graham Dixon, senior vice president of Drug Discovery at Galapagos.